Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 6,57 M
EBIT 2017 -0,94 M
Net income 2017 -1,07 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,78 M
EBIT 2018 -2,59 M
Net income 2018 -2,81 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 7,76x
Capi. / Sales2018 6,55x
Capitalization 50,9 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar

- No events available -

More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
09/08 INTELGENX TECHNOLOGIES : Announces Decisions in Suboxone Patent Litigation
09/07 INTELGENX TECHNOLOGIES CORP. (OTCMKT : IGXT) Files An 8-K Departure of Directors..
09/06 INTELGENX TECHNOLOGIES : Announces Decisions in Suboxone(R) Patent Litigation
09/06 INTELGENX TECHNOLOGIES : Announces Decisions in Suboxone(R) Patent Litigation
08/31 INTELGENX TECHNOLOGIES : Grants Stock Options
08/31 INTELGENX TECHNOLOGIES : Grants Stock Options
08/30 INTELGENX TECHNOLOGIES : to Present at the 19th Annual Rodman & Renshaw Global I..
08/10 INTELGENX TECHNOLOGIES : reports 2Q loss
08/10 INTELGENX TECHNOLOGIES : Reports Second Quarter 2017 Financial Results
08/10 INTELGENX TECHNOLOGIES CORP. : Investor Network: Intelgenx Technologies Corp. to..
More news
Sector news : Generic Pharmaceuticals
02:19pDJEuropean Corporate Roundup for Thursday
11:31aDJEuropean Corporate Roundup for Thursday
08:48aDJMERCK AND : Chenault Among Few Black CEOs -- WSJ
07:53aDJROCHE : 3Q Sales Increase on Strong Performance of Recently Launched Drugs
10/18DJMERCK AND : Amex Retirement Shines Light on Lack of Diversity in CEO Ranks
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 98%
EPS Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director